CriticalAntidepressants. Other antidepressants of herbal origin×Selective serotonin reuptake inhibitor (SSRI)
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1), and paroxetine is a selective serotonin reuptake inhibitor (SSRI). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with SSRIs, including paroxetine (St John's wort SmPC, AEMPS, section 4.5). The European Medicines Agency (EMA) herbal monograph gives paroxetine as an example of an antidepressant whose serotonergic effects St John's wort may add to (St John's wort herbal monograph, EMA, section 4.5). The paroxetine SmPC states that combination with serotonergic agents, St John's wort preparations among them, may lead to 5-HT-associated effects, which can extend to serotonin syndrome (paroxetine SmPC, AEMPS, section 4.5).
Symptoms
According to the Spanish paroxetine summary of product characteristics (SmPC), serotonin syndrome can be life-threatening. Its features are hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, confusion, irritability and extreme agitation that may progress to delirium and coma (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). The paroxetine label of the US Food and Drug Administration (FDA) also lists hallucinations, dizziness, sweating, flushing, tremor, hyperreflexia, incoordination, seizures, nausea, vomiting and diarrhoea (FDA paroxetine label, section 5.2). According to the European Medicines Agency (EMA) herbal monograph, the syndrome occurs very rarely with serotonin reuptake inhibitors (St John's wort herbal monograph, EMA, section 4.5).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), and its interaction table names paroxetine (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The paroxetine SmPC is less strict: it advises caution and close monitoring of the patient when paroxetine is combined with serotonergic agents, St John's wort preparations among them (paroxetine SmPC, AEMPS, section 4.5). If serotonin syndrome occurs, stop paroxetine and start supportive symptomatic treatment (paroxetine SmPC, AEMPS, section 4.4); the label of the US Food and Drug Administration (FDA) also says to stop other serotonergic medicines immediately (FDA paroxetine label, sections 5.2 and 7). No document says how long to wait between stopping St John's wort and starting paroxetine. Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, European Medicines Agency, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5
- AEMPS: Ficha técnica: Paroxetina, Seroxat 20 mg (nº registro 59468), sección 4.5 (2025)– AEMPS, CIMA, nº registro 59468 (Seroxat 20 mg comprimidos recubiertos con película, GlaxoSmithKline), revisión 12/2025, secciones 4.4 y 4.5